Corrigendum: SNORA72 activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells

Liwen Zhang[1,2,3,4†], Rong Ma[1,2,3,4†], Mengcong Gao[1,2,3,4], Yanyun Zhao[1,2,3,4], Xuemei Lv[1,2,3,4], Wenjing Zhu[1,2,3,4], Li Han[1,2,3,4], Panpan Su[1,2,3,4], Yue Fan[1,2,3,4], Yuanyuan Yan[1,2,3,4], Lin Zhao[1,2,3,4], Heyao Ma[1,2,3,4], Minjie Wei[1,2,3,4]* and Miao He[1,2,3,4]*

[1]Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China, [2]Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China, [3]Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China, [4]Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China

---

A Corrigendum on

SNORA72 activates the Notch1/c-Myc pathway to promote stemness transformation of ovarian cancer cells

by Zhang L, Ma R, Gao M, Zhao Y, Lv X, Zhu W, Han L, Su P, Fan Y, Yan Y, Zhao L, Ma H, Wei M and He M (2020). Front. Cell Dev. Biol. 8:583087. doi: 10.3389/fcell.2020.583087

In the original article, there was a mistake in Figure 1 as published. The transwell picture for CA in Figure 1C was mistaken and misused. The corrected Figure 1 appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

FIGURE 1

SNORA72 is overexpressed in ovarian cancer stems cells (OCSCs). **(A)** Morphology of OVCAR-3 (OV), OVCAR-3 spheroid (OS), CAOV-3 (CA), and CAOV-3 spheroid (CS) cells shown under a microscope (×10). **(B)** Expression of CD133 detected by flow cytometry in OV vs. OS and in CA vs. CS cells. **(C)** Migration abilities of OV, OS, CA, and CS cells by Transwell assay. **(D)** Differentiation morphology of OS and CS cells at 0, 12, 24, 48, and 72 h. **(E)** Hierarchical clustering analysis of small nucleolar RNA (snoRNA) expression from non-coding RNA-ChIP data in OV and OS cells. Red, higher expression levels; green, lower expression levels. **(F)** Relative SNORA72 expression to U6, as an endogenous control, analyzed by qRT-PCR in OV and OS cells. The SNORA72 expression in OV cells was set as 1. Data are shown as the mean $\pm$ SD from three independent experiments. **$p < 0.01$, ****$p < 0.0001$.